Back to Results

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Erin Schenk

Erin Schenk

Study ID

Protocol Number: 20-2584

More information available at ClinicalTrials.gov: NCT02922764

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers